IGM Biosciences Inc (IGMS NASDAQ) stock market data APIs
$1.1817
0(0%)
as of March 21, 2025
IGM Biosciences Inc Financial Data Overview
IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M antibodies for the treatment of cancer and autoimmune and inflammatory diseases. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.
Prev. Close
1.1817
Open
1.1817
High
1.2149
Low
1.1604
52 wk Range
1.15-22.5
Market Cap
71 133 K
Shares Outstanding
34 388 K
Revenue
2 679 K
EPS
-0.61
Beta
0.358
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get IGM Biosciences Inc data using free add-ons & libraries
Get IGM Biosciences Inc Fundamental Data
IGM Biosciences Inc Fundamental data includes:
- Net Revenue: 2 679 K
- EBITDA: -185 104 992
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-03-05
- EPS/Forecast: -0.7106
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
IGM Biosciences Inc News
New
IGM Bio (IGMS) Stock Rallies 142% in 3 Months: Here's Why
IGM Biosciences IGMS, a clinical-stage company, is developing a pipeline of Immunoglobin M (IgM) antibody-based candidates to treat patients with cancer and autoimmune and inflammatory diseases. The ...
IGM Biosciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference
IGM Biosciences, Inc. MOUNTAIN VIEW, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM anti...
15 Best Falling Stocks To Buy Now
In this piece, we will take a look at the 15 best falling stocks to buy now. If you want to skip our overview of the current stock market environment and our coverage of the latest stock market news, ...
IGM Biosciences Announces Strategic Pipeline Prioritization and Cash Runway Extension
IGM Biosciences, Inc. – Priorities: clinical development of DR5 agonist in colorectal cancer and T cell engagers in autoimmune disease – – Plans to file IND for IGM-2644 (CD38 x CD3) to treat ...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
